Immunosuppressive therapy in dermatology and PML

J Dtsch Dermatol Ges. 2009 Jan;7(1):5. doi: 10.1111/j.1610-0387.2008.06993.x.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use
  • Dermatology / trends*
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use*
  • Leukoencephalopathy, Progressive Multifocal / chemically induced*
  • Leukoencephalopathy, Progressive Multifocal / prevention & control
  • Male
  • Psoriasis / complications
  • Psoriasis / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Immunosuppressive Agents
  • efalizumab